Posaconazole prophylaxis is recommended for patients with acute myeloid leukaemia during induction chemotherapy. Although a tablet formulation with better oral bioavailability is available, some patients have to rely on the oral suspension in clinical routine. Therefore, effectiveness of posaconazole oral suspension under real-life clinical conditions and impact of patient education about the correct intake on its plasma concentrations were assessed in this study. Altogether 96 patients receiving 160 cycles of induction chemotherapy were retrospectively (40 patients) and prospectively (56 patients) analysed. Patients were assigned into two groups for each chemotherapy cycle according to the application of antifungal prophylaxis (A: posaconazole oral suspension, 200 mg three times a day ≥7 days; B: intake <7 days, fluconazole or no prophylaxis). Antifungal prophylaxis and therapy were analysed for each cycle. Additionally, plasma concentrations were determined from prospectively included subjects of group A who were intensively educated to perform a correct drug intake. Systemic antifungal therapy was statistically started less often in group A (26% vs 53%; P = 0.002). Posaconazole prophylaxis was associated with a lower risk of proven invasive fungal infection (P = 0.003). Median plasma concentration apparently increased between the first and second time of determination effected by an initial intensive on-site patient education. The clinical effectiveness of posaconazole oral suspension was confirmed. A detailed patient education at the beginning of the treatment with posaconazole oral suspensions seems to be of primary importance for efficient plasma concentrations.
| INTRODUCTION
Patients with acute myeloid leukaemia (AML) receiving induction chemotherapy are at high risk of severe invasive fungal infections (IFI), which can become responsible for delay or interruption of treatment. 1 Patient characteristics (age, comorbidity) often influence standardized AML treatment according to practice guidelines. 2 Prophylaxis with the antifungal agent posaconazole reduced the rate of IFI and mortality in AML patients with neutropenia after induction chemotherapy. 3, 4 Although it is therefore strongly recommended by international guidelines, 5, 6 the use of systemic antifungal agents differs from guidelines for various reasons (eg, intolerance, drug interactions) in a substantial number of cases in clinical routine. 7 In comparison with other established broad-spectrum antimycotics, posaconazole is effective against mould as well as yeast infections, has a better safety profile and shows advantages concerning drug-drug interactions. 8 The oral suspension was approved for antimycotic prophylaxis in patients with AML during induction chemotherapy and stem cell transplant recipients with graft-vs-host disease (GVHD) grade II or higher in 2007. Despite its widespread acceptance, the oral suspension has pharmacological limitations. In particular, a low and highly variable oral bioavailability of 10%-50% 9 can result in ineffective plasma concentrations and cause an increased rate of breakthrough IFIs. 10, 11 Due to its lipophilicity, it should be taken together with fatty food to improve the absorption rate. 12 Since 2014, a tablet formulation is available which has solved some of the pharmacological issues. 13, 14 However, patients who are impaired to swallow tablets (eg, due to mucositis, children) in daily clinical routine often have to rely on the oral suspension and thus remain at risk of ineffective plasma concentrations. Among therapeutic drug monitoring, the training of patients for a correct intake of the oral suspension can be a helpful strategy to improve its plasma concentrations. Meaningful data about the influence of medication compliance of posaconazole oral suspension on effective plasma concentrations are lacking. The objectives of this study were to assess the effectiveness of posaconazole oral suspension under real-life clinical conditions and the impact of patient education about the intake on its steady-state plasma concentrations.
| MATERIALS AND METHODS
A retrospective open-label, single-centre observational cohort study with a supplementary prospective part was carried out at the Department of Hematology and Oncology in cooperation with the Department of Clinical Pharmacology and Pharmacoepidemiology of Heidelberg University Hospital (Heidelberg, Germany). The study protocol was approved by the Ethic Committee of the Medical Faculty of Heidelberg University (S-472/2013). It was conducted in accordance with good clinical practice and the Declaration of Helsinki. We obtained written informed consent from each patient for the prospective part of the trial prior to any study-related activity. No written informed consent was available for the retrospective analysed patients.
| Study population
Patients with newly diagnosed or relapsed AML/ myelodysplastic syndrome (MDS) who were admitted to Heidelberg University Hospital and underwent various cycles of induction chemotherapy between October 2010 and December 2014 had to be at least 18 years of age to be admitted to the trial. Exclusion criteria included therapy of AML M3 with retinoic acid, azacitidine monotherapy or insufficient documentation of clinical course.
| Study design
Forty patients admitted to the trial from October 2010 to October 2013 were retrospectively assigned into two groups for each chemotherapy cycle according to the application of antifungal prophylaxis. The latter was prescribed by the treating physicians and neither influenced nor modified by the investigators. Group A received posaconazole prophylaxis (oral suspension, 200 mg three times a day) at least on seven consecutive days during a chemotherapy cycle, assuming that steady-state conditions were reached. Group B received posaconazole prophylaxis (oral suspension, 200 mg three times a day) <7 days, fluconazole prophylaxis or no prophylaxis at all during a chemotherapy cycle. If patients had received different prophylaxis regimens during their various cycles of induction chemotherapy, each cycle was categorized into group A or B, respectively. One cycle (series of chemotherapies followed by a recovery break) was defined as the period between the day of starting with the first infusion of a series of chemotherapies and the day before starting a continuous series of chemotherapies. The number of cycles was chosen individually according to international guidelines by the treating physicians and dependent on the patient's reaction to treatment. In case of a premature patient's discharge during a not completed cycle, the latter was defined as the period between the day of starting with the first infusion of a series of chemotherapies and the day of hospital discharge.
Fifty-six patients admitted to the trial from October 2013 to December 2014 were prospectively assigned into group A and group B as mentioned above. Subjects initially assigned into group A in the prospective part of the study were additionally asked for written informed consent to determine posaconazole plasma concentration in residual amounts of plasma from routine blood drawings. Furthermore, they were intensively educated to perform a correct posaconazole intake during four visits per cycle by the investigators. The necessity for the drug and the indication of antifungal prophylaxis, the correct drug intake together with fat-containing food (eg, cream yoghurt, bread with butter or cheese, cracker) or with an acid coke beverage and patients' questions were thoroughly discussed during the first visit. The subsequent three visits were scheduled after 7 and 14 days after the first visit as well as within 3 days before the end of the cycle, respectively. During these visits, compliance was checked by open questions.
| Data collection
Information about patients' characteristics (sex, age, weight), antifungal prophylaxis and therapy as well as duration, dosage and type of administration of the concomitant medication were obtained by chart abstraction of all electronic and paper documentation. Data were entered in a MS Excel 2010 ® (Microsoft Corporation, Redmond, WA, USA) database.
| Sample collection and determination of posaconazole concentrations
Blood samples for determining posaconazole plasma concentration were collected in residual amounts of plasma from routine blood drawings after at least 7 days of posaconazole prophylaxis and during neutropenia. The blood was kept from collection in lithium heparin tubes in the morning under fasting conditions prior to next dosing (trough level). Blood samples were centrifuged within 30 minutes of drawing, and separated plasma was stored at −20°C until analysis. It was shipped on dry ice to the laboratory of the Department of Internal Medicine II of Wuerzburg University Hospital (Wuerzburg, Germany). After liquid/liquid extraction (diethyl ether; Merck, Darmstadt, Germany), the samples were analysed by means of a validated and published assay using high-performance liquid chromatography (HPLC System; Beckman-Coulter, Krefeld, Germany). 15 The calibration of the method covered the range between 50 and 25.000 ng/mL for posaconazole. The lower limit of quantification in plasma was 50 ng/mL.
| Statistics
Statistical analysis and graphic illustration were performed using Prism 6.0 (GraphPad Software, La Jolla, CA, USA). Descriptive statistics were used to summarize the data. Statistical parameters, such as mean value, standard deviation (±SD), were determined for age and weight. Median, the interquartile range (IQR) and minimum to maximum (range) were determined for the duration of chemotherapy cycles, antifungal prophylaxis or treatment and posaconazole plasma concentrations. Statistical evaluation was performed using nonparametric Fisher's exact test for categorical variables and Mann-Whitney test for continuous variables. A P-value <0.05 was considered statistically significant. The odds ratio (OR) and 95% CI were calculated for dichotomous variables when applicable.
| RESULTS
This trial investigated 96 patients with a mean age of 55 years during a total of 160 chemotherapy cycles. The duration of one cycle did not statistically differ between group A (24 days, range 15-66) and group B (25 days, range 3-71; P = 0.14). AML/MDS was newly diagnosed in 94% of the included patients, whereas 6% presented themselves with a relapse (Table 1) .
| Antifungal prophylaxis
Posaconazole prophylaxis was administered in 95 of the investigated cycles (group A), fluconazole prophylaxis in 44 cycles and no antifungal prophylaxis was given in 15 cycles (group B). Six chemotherapy cycles were excluded from the analysis because posaconazole and fluconazole were given alternately ( Table 2 ). During 20 chemotherapy cycles, posaconazole administration had to be interrupted for various reasons (eg, systemic antifungal treatment) with an average interruption time of 6 (±3) days. The median duration of posaconazole (21 days, range 7-41) and fluconazole (22 days, range 2-47) prophylaxis did not statistically differ (P = 0.73).
| Antifungal treatment
Systemic antifungal therapy had to be started statistically less often in group A (26%) compared to group B (53%; P = 0.002). The median duration of antimycotic treatment 
T A B L E 2 Indication for antimycotic treatment
Group A Group B P-value was 10 (1-55) days in group A vs 14 (1-62) days in group B (P = 0.35). There was no statistically significant difference between both groups regarding systemic antifungal therapy due to empirical indications (P = 0.83); however, statistically significant differences occurred for pre-emptive indications (P = 0.02) or proven IFI (P = 0.003; Table 2 ).
No proven IFI was observed in group A, whereas six occurred in group B (3× Aspergillus spp., 2× Mucor spp., 1× Candida spp.). Posaconazole prophylaxis was associated with a lower risk of proven IFI (OR 0.04, 95% CI 0-0.7, P = 0.003) and less pre-emptive therapy (OR 0.34, 95% CI 0.13-0.84, P = 0.02).
| Patient education and posaconazole steady-state concentrations
Twenty-two patients received an intensive patient education programme during four visits per cycle for a period of two cycles (assuming 176 visits). As two of these patients did not receive posaconazole prophylaxis during their second cycle, 168 educational visits took actually place. During the first visit, it was figured out that approximately 60% of the patients were properly informed about the indication of their posaconazole prescription and the correct intake of the drug by their treating physicians prior to any study-relevant activity. Due to the teaching during the four visits, the knowledge improved and the correct intake of the drug was inquired and confirmed by the patients. Only two patients reported skipping some drug intakes due to nausea.
Posaconazole trough levels at steady-state conditions could be analysed in 56 blood samples of 22 prospectively investigated patients who received the education programme. Five outlier concentrations (from two patients) were excluded due to irregular posaconazole intake as mentioned above. For comparison of the plasma concentrations, four certain time-points were defined, as shown in Table 3 . Median plasma concentrations increased from first to second time-point but stayed nearly constant from there without any statistically significant differences between the different time-points ( Figure 1 and Table 3 ). The median plasma concentration for all visits was 794 ng/mL (IQR 483-1330, range 18-3826).
| DISCUSSION
The oral suspension of posaconazole for antifungal prophylaxis in AML patients today is largely replaced by a tablet formulation with better oral bioavailability. 16 However, a notable number of patients who are impaired to swallow tablets still depend on the oral suspension in real-life clinical routine and therefore ongoing intrinsic research about its effectiveness and safety is crucial. Our real-life clinical data confirm the therapeutic effect of posaconazole oral suspension, as the amount of preemptive antimycotic treatments were significantly reduced and less proven IFI cases were caused if posaconazole oral suspension was used for antifungal prophylaxis. The groups around Kung et al and Vehreschild et al investigated 130 and 159 AML/MDS patients and demonstrated also a remarkable reduction of probable as well as proven IFIs from 19.5% to 3.9% and from 10.8% to 0% using posaconazole oral suspension. 17, 18 All these findings are in line with two large, randomized, controlled trials who achieved a twofold to fourfold reduction of proven and probable IFIs in AML/MDS patients with neutropenia or with severe GVHD. 3, 19 Structured patient education about correct posaconazole oral suspension intake led to an increased rate of sufficient plasma steady-state levels in a study by Hoenigl et al. 20 The exposure-response relationship for posaconazole oral suspension was shown with a logistic regression out of 541 posaconazole plasma concentrations. Median plasma concentrations were accepted to be an independent predictor for breakthrough fungal infections. Patients with breakthrough fungal infections had a median plasma concentration of 289 vs 485 ng/mL in patients without breakthrough infections. 21 Despite an intensive patient education, about 25% of our patients had posaconazole plasma concentrations below 500 ng/mL throughout the trial. However, recent studies recommend trough levels of at least 700 ng/ mL during posaconazole prophylaxis for clinical effectiveness. [22] [23] [24] [25] [26] Following this standard, approximately 50% of the investigated patients would have been considered underexposed, which seems to be in contrast to our presented data about the clinical effectiveness. Although our data set is limited and therefore not suitable to show significance, we observed the trend that median plasma concentration apparently increased between the first and second time-points effected by the initial intensive on-site patient education. The following changes in plasma concentrations during the trial were only slight, which can be an indication that a detailed patient education at the beginning of the treatment with posaconazole oral suspensions is of primary importance for its effectiveness. Nevertheless, benefits of therapeutic drug monitoring should receive attention in this context although it is still not a clinical routine procedure if posaconazole oral suspension is administered for antimycotic prophylaxis. 21, 22, 25 To improve the evidence of these findings, future trials should challenge them with the help of a control group analysing patients not having received an intensified patient education programme. Another limitation of this study is the oral questioning of posaconazole intake by the study team instead of a patient diary documentation. The additional individual analysis of the relation between patient education in combination with obtained plasma levels and actual clinical effectiveness may provide information about confounding factors. Furthermore, the occurrence of mucositis and co-administration of H2 blocker famotidine or proton-pump inhibitor were not assessed and evaluated, which are investigated risk factors for lower oral bioavailability of posaconazole oral suspension. 22, 27 The results of this study confirm the clinical effectiveness of posaconazole oral suspension. A detailed patient education at the beginning of the treatment with posaconazole oral suspensions seems to be of primary importance for efficient plasma concentrations. 
